Sensydia – a non-invasive cardiac assessment company – announced it has raised approximately $8 million in a new round of funding from an expanded syndicate of investors. The proceeds of the funding will enable the company to prepare for the commercialization of its groundbreaking non-invasive cardiac assessment platform Cardiac Performance System (CPS). And Sensydia continues to push the boundaries of its heart-sound AI technology, which promises to transform the diagnosis and management of heart disease (the leading cause of death worldwide).
This funding round was led by Orlando Health Ventures with participation from Colle Capital, Frontier Venture Capital, and others. And concurrent with this financing, Erick Hawkins, Chief Administrative Officer for Orlando Health, will join the Sensydia board of directors.
Sensydia’s CPS platform utilizes ultra-sensitive biosensors and AI algorithms to provide clinicians with rapid and non-invasive measurement of ejection fraction, cardiac output, pulmonary artery pressure, and pulmonary capillary wedge pressure in a handheld device without the need for in-hospital catheterization.
This funding round will enable the company to finalize the development of the CPS platform and submit to the United States Food and Drug Administration (FDA) in 2024 for prioritized review as part of the FDA Breakthrough Devices Program.
“We are thrilled to have the support of investors who share our vision for transforming heart failure management. This funding will enable us to accelerate our march to commercialization by expanding development and operations for our CPS platform.”
— Anthony Arnold, President and CEO of Sensydia
“Sensydia’s CPS technology is a game-changing AI application that makes crucial cardiac data both accessible and affordable. This technology transcends geographical and financial barriers to care, unlocking new markets while enhancing early diagnosis and treatment protocols.”
— Victoria Grace, Founder of Colle Capital and Sensydia Board Member
“Non-invasive and real-time cardiac function measures will lead to early diagnosis and personalized care for heart disease. This technology has the potential to vastly improve patient lives by enabling faster and more affordable disease management, moving healthcare from the hospital setting into the patient’s home.”
— Farhan Khawaja, MD, President of the Orlando Health Heart & Vascular Institute
Trending on Pulse 2.0
- CAT Labs: This Company Is Redefining The $30+ Billion Global Cybersecurity Forensics Technology Market
- AMP Robotics Closes $99 Million To Build Systems That Can Sort Recyclable Materials
- Apple iPad Pro 5 vs iPad Pro 4: Differences You Should Know About
- Huntress: Managed Security Platform Company Raises $60 Million